SFX by Ex Libris Inc.

Title:	Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
Source:	Human Molecular Genetics [0964-6906] Goyenvalle, A yr:2012

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	't Hoen, Dwi A. "Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy." BMC medical genomics 4.1 (2011): 36-36.
description	2.	Vidal, B. "Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor." Human molecular genetics 21.9 (2012): 1989-2004.
description	3.	Wang, Z. "Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy." Human gene therapy 18.1 (2006): 18-26.
description	4.	Malerba, A. "Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy." Molecular Therapy: Nucleic Acids 1.12 (2012).
description	5.	Arakawa, R. "Human first-trimester chorionic villi have a myogenic potential." Cell and tissue research 348.1 (2012): 189-197.
description	6.	Kemaladewi, Dwi U. "Cell-type specific regulation of myostatin signaling." The FASEB journal 26.4 (2011): 1462-1472.
description	7.	Segalat, L. "Duchenne Muscular Dystrophy : Stalled at the junction?" European journal of human genetics 13.1 (2005): 4-5.
description	8.	D'Angelo, Maria G. "Neurocognitive Profiles in Duchenne Muscular Dystrophy and Gene Mutation Site." Pediatric neurology 45.5 (2011): 292-299.
description	9.	Hachiya, A. "Gene transfer in human skin with different pseudotyped HIV-based vectors." Gene therapy 14.8 (2007): 648-56.
description	10.	Boissier, MC. "Immunity against AAV serotypes 1, 2, 5 and 8 as potential obstacle to intra-articular gene therapy." Arthritis and rheumatism 54.9 (2006).
description	11.	Dahlbäck, B. "Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?" Molecular immunology 40.18 (2004): 1333-1346.
description	12.	Acharyya, S. "Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy." The journal of clinical investigation 117.4 (2007): 889-901.
description	13.	High, Katherine A A. "Immune responses to AAV in clinical trials." Current gene therapy 7.5 (2007): 316-24.
description	14.	van Deutekom, Judith C T C. "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy." Neuromuscular disorders 12.SUPPL. (2002): 71-7.
description	15.	Chamberlain, Jeffrey S S. "rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice." Nature medicine 12.7 (2006): 787-9.
description	16.	van Deutekom, J C C. "Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells." Human Molecular Genetics 10.15 (2001): 1547-54.
description	17.	Loizeau, M. "Physicochemical properties of cationic lipophosphoramidates with an arsonium head group and various lipid chains: A structure–activity approach." Biophysical chemistry 171 (2013): 46-53.
description	18.	Bertini, M. "Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation." The journal of pediatrics 161.4 (2012): 705-90.
description	19.	Fairclough, Rebecca J. "Progress in therapy for Duchenne muscular dystrophy." Experimental physiology 96.11 (2011): 1101-1113.
description	20.	Arechavala Gomeza, V. "Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study." Lancet 378.9791 (2011): 595-605.